Johnson & Johnson vs Moderna Which Is Superior?

Johnson & Johnson and Moderna are two prominent pharmaceutical companies that have been making headlines due to their development of COVID-19 vaccines. Johnson & Johnson's single-dose vaccine has been authorized for emergency use, while Moderna's mRNA vaccine has also received widespread approval. Both companies have seen significant fluctuations in their stock prices as investors closely monitor their progress in the fight against the pandemic. This comparison explores the performance of Johnson & Johnson and Moderna stocks in the context of their vaccine developments.

Johnson & Johnson or Moderna?

When comparing Johnson & Johnson and Moderna, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Johnson & Johnson and Moderna.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Johnson & Johnson has a dividend yield of 3.98%, while Moderna has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Johnson & Johnson reports a 5-year dividend growth of 5.83% year and a payout ratio of 79.71%. On the other hand, Moderna reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Johnson & Johnson P/E ratio at 25.33 and Moderna's P/E ratio at -7.29. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Johnson & Johnson P/B ratio is 5.30 while Moderna's P/B ratio is 1.36.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Johnson & Johnson has seen a 5-year revenue growth of 0.10%, while Moderna's is 10.71%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Johnson & Johnson's ROE at 20.94% and Moderna's ROE at -17.68%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $151.42 for Johnson & Johnson and $41.71 for Moderna. Over the past year, Johnson & Johnson's prices ranged from $143.13 to $168.85, with a yearly change of 17.97%. Moderna's prices fluctuated between $41.54 and $170.47, with a yearly change of 310.38%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.